Radiotherapy

PSA level prior to salvage radiotherapy may be a prognostic biomarker for clinical outcomes of long-term antiandrogen therapy with salvage radiotherapy among men with prostate cancer, according to results of a secondary analysis of a randomized trial published in JAMA Oncology.

A 5-day regimen of neoadjuvant radiotherapy appeared as effective and safe as the conventional 5-week regimen for patients with soft tissue sarcoma, according to results of a prospective phase 2 study published in Clinical Cancer Research.

Neoadjuvant chemotherapy did not appear to expedite treatment compared with adjuvant chemotherapy for women with breast cancer, according to study findings published in Cancer Medicine.

PHILADELPHIA — Ocular melanoma patients who received prophylactic bevacizumab with plaque radiotherapy experienced significantly better visual acuity outcomes than control patients who did not receive bevacizumab, according to a speaker here.

Pembrolizumab in combination with radiotherapy conferred promising survival outcomes with acceptable toxicity among patients with locally advanced head and neck squamous cell carcinoma, according to results of a single-arm phase 2 study presented at Multidisciplinary Head and Neck Cancers Symposium.

Patient-reported adverse effect profiles 5 years after contemporary treatment for localized prostate cancer could help inform treatment choices for this patient population, according to study results published in JAMA.

The FDA granted fast track designation to NBTXR3, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell carcinoma who are not eligible for platinum-based chemotherapy, according to a company-issued press release.

Click here to read the Cover Story, “Cure for childhood cancer may come at the cost of premature aging.”

A 21-gene recurrence score appeared useful for assessing locoregional recurrence risk among certain postmenopausal women with breast cancer who underwent whole-breast radiotherapy or mastectomy without postmastectomy radiotherapy, according to results of an analysis of the phase 3 SWOG S8814 study published in JAMA Oncology.

Actinium Pharmaceuticals has forged an agreement with University of California, Davis for the use of its proprietary CD45 antibody radiation-conjugate, apamistamab-I-131, in the institution’s ongoing phase 1/phase 2 clinical trial of stem cell gene therapy for patients with HIV-related lymphoma.